Endothelin antagonists and the quest for a new therapeutic option in resistant hypertension

Affiliations

¹ Experimental and Clinical Research Center, University and Max Delbrück Center for Molecular Medicine, Berlin 13125, Germany; Departments of Cardiology and Nephrology, Helios Clinic Berlin-Buch, Germany. Electronic address: ralf.dechend@charite.de.
² School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.

Comment

Ralf Dechend et al. Lancet. 2022.

. 2022 Dec 3;400(10367):1900-1901.

doi: 10.1016/S0140-6736(22)02181-X. Epub 2022 Nov 7.

¹ Experimental and Clinical Research Center, University and Max Delbrück Center for Molecular Medicine, Berlin 13125, Germany; Departments of Cardiology and Nephrology, Helios Clinic Berlin-Buch, Germany. Electronic address: ralf.dechend@charite.de.
² School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.

No abstract available

Comment on

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, Dreier RF, Sassi-Sayadi M, Haskell LP, Narkiewicz K, Wang JG; PRECISION investigators. Schlaich MP, et al. Lancet. 2022 Dec 3;400(10367):1927-1937. doi: 10.1016/S0140-6736(22)02034-7. Epub 2022 Nov 7. Lancet. 2022. PMID: 36356632 Clinical Trial.